News | Biopsy Systems | March 16, 2017

First Canadian customer will use prostate biopsy system in study to better understand apoptosis and how cancerous cells respond to therapy

Exact Imaging, Health Canada approval, ExactVu micro-ultrasound system, prostate biopsies, Sunnybrook Health Sciences Centre, Gregory Czarnota

March 16, 2017 — Exact Imaging has received Health Canada approval and the corresponding medical device license (#98667) to sell its ExactVu high resolution micro-ultrasound biopsy system in Canada. The first device was sold to Gregory Czarnota, M.D., and Sunnybrook Health Sciences Centre and Sunnybrook Research Institute in Toronto.

"The unmatched resolution of the ExactVu micro-ultrasound system will provide important capabilities to our urologists in helping them actually visualize and distinguish suspicious tissue — and therefore allows us to actually target our prostate biopsies," said Czarnota, director of the Odette Cancer Research Program, Sunnybrook Research Institute and Radiation Oncologist at Sunnybrook Health Sciences Centre. "Furthermore, the ExactVu's high resolution imaging also generates rich RF (or radiofrequency) data which our research teams can evaluate and correlate with pathology to apply against our models to better understand apoptosis and how cancerous cells respond to therapy. We see very exciting potential in the ExactVu system and look forward to our collaboration with the team at Exact Imaging."

Czarnota discovered that high-frequency ultrasound could be used to detect apoptosis or cell death. This finding has since been applied to important questions in oncology and organ transplantation. Czarnota's research group is investigating a number of spectroscopic parameters for characterizing tumors and tumor responses to chemotherapy and radiation therapy at high frequencies and intends to use the ExactVu for such purposes. Specific applications include developing methods to generate color-coded ultrasound parametric maps to aid in assessing tumor responses to therapy. Since these spectroscopic signals are potentially linked to nuclear structure and chromatin structure that differs between normal and neoplastic tissue, there is potential to develop our spectroscopic methods not only into a method to track tumor responses but a potentially important diagnostic tool.

For more information: www.exactimaging.com


Related Content

News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | Radiology Business

July 19, 2024 — GE HealthCare announced it has entered into an agreement to acquire Intelligent Ultrasound Group PLC’s ...

Time July 19, 2024
arrow
Feature | Women's Health | By Jordan Bazinsky

Investing in women’s health should not merely be a metric on the equity dashboard — it should drive policy and tactical ...

Time July 08, 2024
arrow
News | Ultrasound Women's Health

June 18, 2024 — The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) has announced details of ...

Time June 18, 2024
arrow
News | Artificial Intelligence

June 17, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time June 17, 2024
arrow
News | Radiopharmaceuticals and Tracers

June 7, 2024 — Shine Technologies, LLC, a pioneer in next-generation fusion-based technology, today announced a new ...

Time June 07, 2024
arrow
News | Radiology Business

May 29, 2024 — Strategic Radiology added a third California member to the nation’s leading coalition of independent ...

Time May 29, 2024
arrow
News | Point-of-Care Ultrasound (POCUS)

May 20, 2024 — Exo (pronounced “echo”), a medical imaging software and devices company, announced the release of Exo ...

Time May 20, 2024
arrow
News | Radiology Imaging

May 13, 2024 — National Basketball Association (NBA), the National Basketball Players Association (NBPA), and the Next ...

Time May 13, 2024
arrow
News | Contrast Media

April 24, 2024 — The International Contrast Ultrasound Society (ICUS) and Northwest Imaging Forums (NWIF) announced an ...

Time April 24, 2024
arrow
Subscribe Now